Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 9

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

552

HTML

6043

Figures (1-2)

215

Tables (1-4)

212

Sum=7022

Sep 15, 2012 (publication date) through Nov 3, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Diabetes. Sep 15, 2012; 3(9): 161-169
Published online Sep 15, 2012. doi: 10.4239/wjd.v3.i9.161

Table 3 Change in HbA1c in patients with an HbA1c-value of ≥ 6.5% at initial visit n (%)

Changes	Vildagliptin add-on to metformin	Vildagliptin + metformin (SPC)	Other OADs
Patients with an HbA1c-value of ≥ 6.5% at initial visit	n = 553	n = 2033	n = 741
Patients with improvement in HbA1c at the last control visit compared to baseline	319 (57.7)	1242 (61.1)	336 (45.3)
Of these, patients with HbA1c value of < 6.5% at the last control visit	140 (25.3)	477 (23.5)	147 (19.8)

OADs: Oral antidiabetic drugs; SPC: Single pill combination.

Citation: Blüher M, Kurz I, Dannenmaier S, Dworak M. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 2012; 3(9): 161-169
URL: https://www.wjgnet.com/1948-9358/full/v3/i9/161.htm
DOI: https://dx.doi.org/10.4239/wjd.v3.i9.161